BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7201835)

  • 1. [Effective levels of cyclophosphamide and metabolites in pleural effusions during intravenous therapy (author's transl)].
    Wagner T; Heydrich D
    Arzneimittelforschung; 1982; 32(5):566-8. PubMed ID: 7201835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of cyclophosphamide and cyclophosphamide metabolites in the mouse and their influence on the therapeutic effect of "activated" cyclophosphamide (4-hydroxycyclophosphamide) (author's transl)].
    Voelcker G; Haeglsperger R
    Arzneimittelforschung; 1982; 32(6):639-47. PubMed ID: 7202370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
    Wagner T; Heydrich D; Bartels H; Hohorst HJ
    Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients.
    Williams ML; Wainer IW; Granvil CP; Gehrcke B; Bernstein ML; Ducharme MP
    Chirality; 1999; 11(4):301-8. PubMed ID: 10224657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)].
    Wagner T; Heydrich D; Voelcker G; Hohorst HJ
    J Cancer Res Clin Oncol; 1980 Jan; 96(1):79-92. PubMed ID: 7358774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of soluble interleukin 2 receptor in differentiating tuberculous and carcinomatous pleural effusions.
    Chang SC; Hsu YT; Chen YC; Lin CY
    Arch Intern Med; 1994 May; 154(10):1097-101. PubMed ID: 8185423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laser high performance liquid chromatography determination of prostaglandins in pleural effusions.
    Ikuta N; Sugiyama S; Takagi K; Hayakawa T; Ozawa T
    Biochem Mol Biol Int; 1995 Jul; 36(3):521-7. PubMed ID: 7549950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.
    Lien EA; Solheim E; Lea OA; Lundgren S; Kvinnsland S; Ueland PM
    Cancer Res; 1989 Apr; 49(8):2175-83. PubMed ID: 2702659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy.
    Joqueviel C; Martino R; Gilard V; Malet-Martino M; Canal P; Niemeyer U
    Drug Metab Dispos; 1998 May; 26(5):418-28. PubMed ID: 9571223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
    Yule SM; Price L; Pearson AD; Boddy AV
    Clin Cancer Res; 1997 Nov; 3(11):1985-92. PubMed ID: 9815588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
    Voelcker G; Wagner T; Hohorst HJ
    Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of 5-fluorouracil and its permeation in pleural effusions in the therapy of metastatic breast cancer].
    Wagner T
    Onkologie; 1984 Feb; 7(1):22-6. PubMed ID: 6369203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
    Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
    Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
    Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
    Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.
    Alemán C; Alegre J; Monasterio J; Segura RM; Armadans L; Anglés A; Varela E; Ruiz E; Fernández de Sevilla T
    Clin Sci (Lond); 2003 Nov; 105(5):601-7. PubMed ID: 12826021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intracavitary chemotherapy of S 180 ascites sarcoma in mice with 4-(S-ethanol)-sulfido-cyclophosphamide in combination with protector thiols].
    Voelcker G; Jaschke A; Wrabetz E; Hohorst HJ
    Arzneimittelforschung; 1984; 34(10):1291-8. PubMed ID: 6440565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ferritin, interleukin-6, interleukin-8 and tumor necrosis factor alpha in the differentiation of exudates and transudates in pleural effusions.
    Alexandrakis MG; Coulocheri SA; Bouros D; Eliopoulos GD
    Anticancer Res; 1999; 19(4C):3607-12. PubMed ID: 10629659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
    Boal JH; Ludeman SM; Ho CK; Engel J; Niemeyer U
    Arzneimittelforschung; 1994 Jan; 44(1):84-93. PubMed ID: 8135883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
    Struck RF; Alberts DS
    Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of telomerase activity between malignant and tuberculous pleural effusions.
    Maneechotesuwan K; Lertworawiwat A; Tscheikuna J; Wamanuttajinda V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S46-54. PubMed ID: 17718245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.